The Path Towards Effective Respiratory Syncytial Virus Immunization Policies: Recommended Actions
RSV causes a substantial burden worldwide. After over six decades of research, there is finally a licensed immunization option that can protect the broad infant population, and other will follow soon.
|
ESWI Airborne: Burden of Disease
Burden of disease - A focus on acute respiratory viruses in older adults
Why should older adults be particularly careful of acute respiratory viruses? What are risk factors for adverse outcomes? Why is RSV typically under-diagnosed in adults compared with flu and what are some of the long-term impacts?
|
ESWI Airborne: Burden of Disease
Burden of disease - The economic and societal impact of acute respiratory viruses
The shocking numbers of babies and children who die, or who are in need of care, coupled with the rising number of undiagnosed older adults puts a significant burden from RSV on health systems.
News
Policy & Recommendations
European Commission authorises first vaccine to protect older adults from RSV infection
The EC has authorised Arexvy, the first vaccine to protect adults aged 60 years and older, against RSV. This decision marks an important step and has been particularly awaited in light of the increased RSV infections in the EU last winter.
Progress Report: Reducing the Burden of RSV across the Lifespan
The National Foundation for Infectious Diseases (NFID) supports RSV education by engaging key audiences, sharing firsthand experiences of RSV among all age groups, and providing resources to help raise awareness of the burden of disease.
ReSViNET's RSV Dashboard is ๐๐๐๐!
ReSViNET Foundation is supporting healthcare decisions by providing transparency and accessibility to shared global RSV surveillance data. The dashboard will help simplify tracking changes in RSV seasonality globally.
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
RSV infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown.
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
Whether vaccination during pregnancy could reduce the burden of RSV associated lower respiratory tract illness in newborns and infants is uncertain.
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study
Accurate health-care burden data in healthy infants are necessary to determine RSV immunisation policy when RSV immunisation becomes available.
Estimation of the number of RSV-associated hospitalisations in adults in the European Union
RSV is a major cause of lower respiratory tract infections in older adults. Estimating RSV- associated hospitalisation is critical for planning RSV-related healthcare needs for the ageing population across Europe.
News
Reports
Policy & Recommendations
Policy priorities for protecting adults at risk of severe illness from RSV
IFA participated in the generation of a new report by the Health Policy Partnership to build awareness of the impact of RSV in adults and highlight opportunities to reduce its burden on society through appropriate prevention, diagnosis, and care.
|
ESWI Airborne: Meet the Members
Celebrating ESWI 30 years!
Who would have taken virus isolation for granted 30 years ago? How and why did ESWI transform from a pure virology-based network to one encompassing a public health perspective?